Antibody Drug Conjugates
Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...
September 11, 2026 | News
Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo
Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...
September 10, 2026 | News
US FDA Clears Acepodia’s ACE723 IND for Phase I Trial in Liver Cancer
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development Acepodia (6976: TT)...
September 07, 2026 | News
DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming furth...
August 31, 2026 | News
WuXi XDC H1 2026 Revenue Jumps 37% to RMB 3.7 Bn on Strong Bioconjugate Demand
Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2]...
August 26, 2026 | Company results
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
Akeso, Inc. announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearanc...
August 24, 2026 | News
Henlius, Sandoz Expand Global Biosimilars Alliance with Up to 10 New Antibody Assets
Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs...
August 18, 2026 | News
Biocon Launches Interchangeable YESAFILI Biosimilar to EYLEA in the U.S.
Yesafili™ (aflibercept-jbvf) now available in the United States as an U.S. FDA-approved interchangeable biosimilar to EYLEA 2 mg Potential ...
August 06, 2026 | News
Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...
August 03, 2026 | News
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...
July 29, 2026 | News
Biointron Launches RushData to Accelerate AI-Driven Antibody Discovery with High-Throughput Experimental Validation
1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design Custom workflows for ...
July 28, 2026 | News
ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...
July 27, 2026 | News
Samsung Bioepis Secures Exclusive Commercial Rights to Nectin-4 ADC Candidate SBE303
Ÿ Under the agreement, Samsung Bioepis will obtain exclusive commercial licensing rights to SBE303, an ADC candidate currently in joi...
July 24, 2026 | News
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 22, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
